---
schema_version: "secwatch.filing_event.v1"
accession: "0001823239-23-000087"
form_type: "8-K"
ticker: "MRVI"
cik: "0001823239"
company_name: "MARAVAI LIFESCIENCES HOLDINGS, INC."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T17:03:01.261058+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Maravai Q3 revenue down 65% to $66.9M, net loss of $15.1M; cuts ~100 jobs to save $30M annually

## Summary
- Q3 revenue $66.9M (-65% YoY); net loss $15.1M vs net income $99.7M a year ago.
- Nucleic Acid Production revenue $51.2M (-71% YoY); COVID-19 CleanCap demand fell $111.6M from prior year.
- Cost realignment targets $30M annual savings, workforce reduction of ~15% (~100 employees) with $5M one-time severance.
- Full-year 2023 guidance lowered to revenue $275-285M; Adjusted EBITDA margin 18% in Q3.
- Partnerships with Thermo Fisher, Intellia, Elixirgen, Precision BioSciences for mRNA cap analogs.

## SEC filing metadata
- accession: 0001823239-23-000087
- form_type: 8-K
- ticker: MRVI
- cik: 0001823239
- company_name: MARAVAI LIFESCIENCES HOLDINGS, INC.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000087/0001823239-23-000087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000087/mrvi-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001823239-23-000087
- JSON: https://secwatch.observer/filing/0001823239-23-000087.json
- Plain text: https://secwatch.observer/filing/0001823239-23-000087.txt

## Key facts
- Earnings Releases
  MARAVAI LIFESCIENCES HOLDINGS, INC. reported the third quarter ended September 30, 2023 results: revenue $66.9 million, net income Net loss of $(15.1) million. Guidance reaffirmed.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $66.9 million
  - Net income: Net loss of $(15.1) million
  - Guidance: reaffirmed
  - Result: reported results
  source text: reported financial results for the third quarter ended September 30, 2023, together with other business updates. Recent highlights include: Financial: • Quarterly revenue of $66.9 million, Net loss of $(15.1) million, and Adjusted EBITDA margin of 18%; and • Updated financial guidance for the full year 2023 to a revenue range of $275.0 million to $285.0 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1823239/000182323923000087/0001823239-23-000087-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.